Navigation Links
CardioDynamics Reports Eighth Consecutive Quarterly Revenue Increase Over Prior Year and 12% Revenue Growth in 2008

Achieves Positive Operating Cash Flow in Fourth Quarter

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) Impedance Cardiography (ICG) technology, today reported financial results for its fourth quarter and fiscal 2008.

Key Financial and Operating Results for Fourth Quarter 2008 Compared with Fourth Quarter 2007

  • Net ICG sales increased 6% to $6.5 million, up from $6.2 million
  • ICG sensor revenue increased 11% to $1.9 million, or 29% of total sales, up from $1.7 million
  • ICG monitor and module sales increased 32% to 291 units, 108 of which were BioZ Dx systems, 9 BioZ monitors, 21 Medis monitors and 153 BioZ modules, up from a total of 221 ICG monitors and modules
  • ICG gross profit margin was 71%, up from 65%
  • Operating loss was $0.4 million, down from $0.8 million, an improvement of 47%
  • $276,000 of cash flow generated from operations compared with a $234,000 operating cash use

Key Financial and Operating Results of Fiscal 2008 Compared with Fiscal 2007

  • Net ICG sales increased 12% to $24.5 million, up from $21.9 million
  • International sales increased 73% to $4.7 million, up from $2.7 million
  • 994 ICG monitors and modules sold, up 32% from 752, now with over 8,700 ICG monitors and modules sold to date
  • ICG gross profit margin was 72%, up from 68%
  • Operating loss improved 58% to $2.0 million, down from an operating loss of $4.8 million which includes $1.0 million of non-cash charges for depreciation, amortization and equity compensation in 2008, and $0.9 million in 2007

Additional Key Operating Milestones for the Fourth Quarter and Fiscal 2008

  • Clinical:
    • Announced results of significant clinical study with nearly three times the national average blood pressure control rates at the American Society of Hypertension annual meeting;
    • Announced two important clinical studies correlating BioZ ICG with Ejection Fraction
    • BioZ ICG technology featured in American College of Cardiology (ACC) audio series
  • Sales & Marketing
    • Launched Comprehensive Customer Care (C3) program designed to improve ICG customer care, satisfaction and proper utilization
    • Initiated BioZ ICG CERTIFIED program, a global approach to ICG education extending from patients to all call points in physician offices and beyond to insurance payers, medical schools and patient advocacy groups.
  • Product:
    • BioZ ICG technology integrated with General Electric Healthcare's Centricity electronic medical record (EMR) system
  • Investor Relations:
    • California Equity Research, LLC, a leading independent investment research firm focused on California equities initiated coverage of CardioDynamics

Fourth Quarter and Fiscal 2008 Operating Results Discussion

The Company reported a net sales increase of 6% to $6.5 million in the fourth quarter 2008 and 12% for full year 2008 to $24.5 million, representing the second consecutive year of growth. Fourth quarter ICG sales growth was driven by a combination of a 13% increase in BioZ sales, a 255% increase in ICG Module sales and an 11% increase in ICG sensor revenue.

ICG Module sales were particularly strong in the fourth quarter with purchases by General Electric Medical Systems (GEMS) of 72 ICG Modules and Mindray of 80 ICG Modules. The Company also received a firm purchase order in January 2009 from Mindray for an additional 150 ICG Modules deliverable in 2009.

ICG sensor revenue in the fourth quarter was a record $1.9 million, due in part to the clinical sales team's focused customer service efforts through the launch of the Comprehensive Customer Care (C3) and ICG CERTIFIED programs.

Gross margin as a percentage of sales increased from 68% to 72% in fiscal 2008, largely due to lower manufacturing overhead costs, 9% average unit sales price improvement, and lower inventory reserve requirements.

As part of the Company's efforts to accelerate the return to profitability, tight expense control resulted in a 1% overall reduction in 2008 operating expenses with the most significant savings occurring in non revenue generating areas including General and Administrative expenses, down $321,000 and Research and Development, down $188,000. The Company surpassed one of its major 2008 goals by achieving $276,000 of positive operating cash flow in the fourth quarter of 2008.

Fourth Quarter 2008 operating loss improved 47% to $442,000, down from an operating loss of $830,000 in fourth quarter 2007. The operating loss for fiscal 2008 was $2.0 million, a 58% improvement from fiscal 2007 operating loss of $4.8 million. Fiscal 2008 loss before income taxes, depreciation, amortization and equity compensation was $1.0 million, an improvement of $2.9 million, or 74%

CEO Comments and Outlook

"We were pleased with the continued improvement in our key operating metrics during the fourth quarter and throughout 2008," stated Michael K. Perry, Chief Executive Officer of CardioDynamics. "Despite the challenging business climate, we achieved our eighth consecutive quarter of revenue growth and accomplished our goal of generating positive operating cash flow, which was $276,000 during the quarter. Our recently introduced Comprehensive Customer Care (C3) and BioZ Certification programs helped grow recurring sensor revenue 11% during the quarter and should contribute appreciably to our growth plans in 2009. International, New Markets and our Medis team were particularly strong contributors on the revenue front, collectively growing 73% in 2008."

Perry continued, "We are conservatively planning for high single to low double-digit revenue growth in 2009 and have, as a major objective, achievement of positive operating cash flow for the entire year. With over $6 million in cash, we have the financial resources to continue to execute our business plan without the need to access the capital markets during these challenging times."

Perry concluded, "Looking out over the next two to three years, we hope to be able to achieve solid growth and improved operating performance with our unique technology in a niche market that is less than 6% penetrated and at the very early stages of market adoption. We believe that we may be well positioned to capitalize on the proposed Obama-Biden healthcare reform which focuses on supporting disease management programs as over 75% of total health care dollars are spent on patients with one or more chronic conditions, including diabetes, heart disease and high blood pressure. ICG is ideal to support the disease management programs for heart disease and hypertension."

Conference Call Information

Michael K. Perry, Chief Executive Officer, and Steve P. Loomis, Chief Financial Officer, will host a summary of CardioDynamics' fourth quarter and fiscal 2008 results in a conference call today, Thursday, February 5, 2009, at 4:30 p.m. (EDT). To access the conference call, dial 800-346-7359 (Code 7784). International participants can call 973-528-0008 (Code 7784). A replay of the call will be available for one month following the call at 800-332-6854 (Code 7784). The international replay number is 973-528-0005 (Code 7784). The Internet webcast can be accessed through the Investor Relations section of the Company's website at or at:

About CardioDynamics

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called BioZ(R) Impedance Cardiography (ICG). The Company develops, manufactures and markets noninvasive BioZ(R) ICG products. The Company's BioZ(R) ICG Systems are being used by physicians around the world to help battle the number one killer of men and women - cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems, and Mindray. For additional information, please refer to the company's Web site at

Forward-Looking (Safe Harbor) Statement

Except for historical and factual information contained herein, this press release contains forward-looking statements, such as expectation of continued revenue growth including high single to low double-digit revenue growth in 2009, the achievement of positive operating cash flow in 2009, continued improvement in our key operating metrics, expectation of solid growth and improved operating performance over the next two to three years, and the adequacy of our financial resources, the accuracy of which is necessarily subject to uncertainties and risks including the Company's primary dependence on the BioZ product line, and various uncertainties characteristic of early stage companies, as well as other risks detailed in the Company's filings with the SEC, including its 2007 Form 10-K. The Company does not undertake to update the disclosures contained in this press release.

                       CardioDynamics International Corporation
                    In thousands, except per share data (unaudited)

    Selected Consolidated
     Operational Results
                                      Three Months Ended  Twelve Months Ended
                                          November 30,         November 30,
                                         2008      2007      2008      2007

    Net sales                           $6,509    $6,151   $24,517   $21,850
    Cost of sales                        1,910     2,157     6,976     6,897
    Gross margin                         4,599     3,994    17,541    14,953
    Research and development               448       389     1,518     1,706
    Selling and marketing                3,976     3,679    15,088    14,780
    General and administrative             593       723     2,839     3,160
    Amortization of intangible assets       26        32       122       147
    Loss from operations                  (444)     (829)   (2,026)   (4,840)
    Other expense, net                    (166)     (166)     (699)     (846)
    Loss before income taxes and
     minority interest                    (610)     (995)   (2,725)   (5,686)
    Minority interest in income of
     subsidiary                            (35)      (33)     (180)      (78)
    Income tax (provision) benefit          78      (126)     (441)     (321)
    Income (loss) from discontinued
     operations                              -         -       127   (10,614)
    Net loss                             $(567)  $(1,154)  $(3,219) $(16,699)
    Net loss per common share:
      Basic and diluted                 $(0.08)   $(0.16)   $(0.45)   $(2.38)
    Weighted-average shares used in
     per share calculation:
      Basic and diluted                  7,223     7,045     7,184     7,014

    Selected Consolidated Balance Sheet Data      November 30,
                                               2008         2007
    Cash and cash equivalents                 $6,306       $8,362
    Accounts receivable, net                   3,918        4,475
    Inventory, net                             1,490        1,948
    Total current assets                      12,138       15,442
    Long-term assets                           3,428        4,425
    Total assets                              15,566       19,867
    Total current liabilities                  4,499        5,620
    Long-term liabilities                      4,504        4,318
    Total liabilities                          9,003        9,938
    Minority interest                            472          407
    Shareholders' equity                       6,091        9,522

SOURCE CardioDynamics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CardioDynamics Announces Investors Retain $5.25 Million 8% Convertible Debt Securities
2. CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008
3. CardioDynamics Announces Second Quarter 2008 Conference Call and Webcast
4. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
5. CardioDynamics Reports 22% Revenue Growth in First Quarter 2008
6. CardioDynamics Board of Directors Proposes Reverse Split 1:7 of Companys Shares
7. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
8. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
9. CardioDynamics Announces Third Quarter 2007 Conference Call and Webcast
10. Cepheid Reports Fourth Quarter and Full Year 2008 Results
11. Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008
Post Your Comments:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: